AI & ML in action: Unlocking RWD with GenAI through Tempus Lens

Edwin M. Posadas, MD, FACP, KM, is the Co-Director of the Experimental Therapeutics Program and the Medical Director of the Center for Uro-Oncology Research Excellence (CURE) at the Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center. He has both clinical and research interests in the treatment of urologic cancers with a special focus on advanced prostate cancer and the biology of cancer metastasis. Dr. Posadas is working to define the function of FYN, CTCs, EVs, and ICs in prostate, kidney, and bladder cancer, with the goal of applying his basic science findings to the development of new therapies and diagnostic tools that will directly benefit men with advanced prostate cancer.

Dr. Josh Watson started his academic career at Appalachian State University earning a B.S. in Cell and Molecular Biology, but in his undergraduate thesis research, found a talent and interest in bioinformatics. For graduate school at the University of Georgia, he studied cross-species comparative oncology between human and canine mammary cancer, discovering a canine subtype that could serve as a model for basal-like breast cancer. Since joining Cedars-Sinai and the Posadas lab in January 2024, Josh has specialized in the bioinformatics side of prostate cancer liquid biopsy research.In his spare time, he enjoys standup paddleboard racing and swimming.

Jess Huang is VP and GM of the Lens at Tempus, where she is driving innovation in genomics, AI and data-driven healthcare solutions. Her work bridges innovative technology with transformative solutions to drive oncology research and insights.

Dr. Maria Berezina is the VP of Real World Data at Tempus, where she oversees clinical data structuring, data model development, and the RWD/RWE analytics. With a decade of experience in oncology analytics, she provides business and research insights to large pharmaceutical companies, biotechs, start-ups, investment funds, and insurance providers. Over the past five years, she has built and led RWD analytics and data science teams, overseeing numerous retrospective studies for life science partners. Her blend of technical expertise, deep knowledge of clinical care in oncology, and experience in RWE generation ensures that Tempus' multi-modal RWD product aligns with life science research goals. She holds a bachelor's degree in Electrical Engineering from the University of Massachusetts Lowell and a doctoral degree in Biomedical Engineering from the Harvard-MIT Division of Health Science and Technology.

Dr. Kathleen Burke is a Senior Director of Computational Biology supporting the Tempus strategic alliances. This team collaborates across companies to drive multimodal analysis that accelerates projects throughout the discovery pipeline by enhancing trial design, broadening biomarker testing, investigating combination opportunities, identifying novel targets, and more. Before coming to Tempus, Kathleen worked at AstraZeneca in the bioinformatics group supporting the Early Oncology Translational Medicine, analyzing molecular data for Hematology drug teams with a focus on determining mechanisms of resistance to Acalabrutinib. She received her PhD in Biomedical Engineering from the University of Rochester and performed post-doctoral research at Memorial Sloan Kettering Cancer Center, understanding the genetic landscape of rare breast/uterine carcinomas.